Phase 3 Randomized Controlled Trial of Androgen Deprivation Therapy with or Without Docetaxel in High-risk Biochemically Recurrent Prostate Cancer After Surgery (TAX3503)
Michael J. Morris(Dana-Farber Cancer Institute), Howard I. Scher(Memorial Sloan Kettering Cancer Center), Julie Filipenko(Cancer Clinic), Glenn Heller(Memorial Sloan Kettering Cancer Center), Andrew J. Armstrong(Duke University), Fred Saad(Centre Hospitalier de l’Université de Montréal), José Maurício Mota(Universidade de São Paulo), Martin Gleave(University of British Columbia), Kristine Peregrino Lacuna(Memorial Sloan Kettering Cancer Center), Michael A. Carducci(Sidney Kimmel Comprehensive Cancer Center), Neal D. Shore(Carolina Urologic Research Center), Patrick Hilden(Memorial Sloan Kettering Cancer Center)
Cited by 20
Related Papers
Tumor mutational load predicts survival after immunotherapy across multiple cancer types
|Nature Genetics|2019|4.4k
Integrative Clinical Genomics of Advanced Prostate Cancer
|Cell|2015|3.6k
Enzalutamide in Metastatic Prostate Cancer before Chemotherapy
|New England Journal of Medicine|2014|3k
Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer
|New England Journal of Medicine|2015|2.8k
Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy
|New England Journal of Medicine|2012|2.8k